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OBJECTIVES: 1) To assess if a translatability assessment (TA) conducted prior  
to a psychometric evaluation in PRO instrument development could predict 
items subsequently eliminated, and 2) to provide evidence to the extent to which 
a TA adds value to the translation and cultural adaptation of PRO instruments. 
The Youth Quality-of-Life Instrument–Weight module (YQOL-W) was chosen as a 
candidate questionnaire for this exercise. METHODS: A team of two linguists, 
blinded to the results of psychometric analyses and decisions on item reduction, 
conducted a TA on the 32-item pre-final version of the YQOL-W. Results were 
categorized into several types of issues. Items for possible deletion  
were identified and compared to the results of the item-reduction phase, using 
both qualitative and psychometric methods performed by the developer. 
RESULTS: During the item-reduction phase, 11 items were dropped; seven for 
qualitative reasons (items 10, 30, 31, 27-32) and four for weak factor loading 
(items 14, 16, 18, 19). Out of the 11 items dropped, TA identified nine problematic 
items (82%) and, among them, advised dropping five items (45.4%), either for 
redundancy with others (items 14, 19, 29, and 32) or inconsistency of construct 
with respect to concept (item 27). For item 28, TA recommended changing the 
original for semantic reasons. For items 10, 30, and 31, TA recommended using 
alternative wording for translation purposes but did not suggest changing the 
original. Finally, for items 16 and 18, TA recommended no changes. 
CONCLUSIONS: Our study showed that a translatability assessment can 
anticipate results of the item-reduction phase. Although more empirical studies 
are needed, we have demonstrated that the involvement of linguists in the early 
development phase could be a plus in detecting irrelevant or inappropriate 
items, and that a translatability assessment can be a useful step in PRO 
instrument development.  
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DOES COMPARATIVE EFFECTIVENESS RESEARCH INCREASE ECONOMIC 
EFFICIENCY?  
Samnaliev M 
Children's Hospital Boston, Boston, MA, USA  
OBJECTIVES: We explore whether comparative effectiveness research (CER) can 
in principle increase economic efficiency. METHODS: The definition and goals of 
CER are compared with the principles of economic theory. The implications 
when the two diverge are discussed. RESULTS: CER is frequently defined to 
include measurement of clinical benefits and harms. Economic efficiency on the 
other hand depends on individuals’ preferences for the health technology under 
consideration relative to other health or non-health commodities (e.g., following 
the Grossman’s utility model). The distinction is important because choosing the 
most clinically effective interventions as the end goal of CER may increase but 
fail to maximize societal welfare if other (e.g. non-health related) factors have 
greater marginal impact on patient or family utility. We present examples which 
may help explain why preferred care is not reimbursable and prescribed 
treatment not adhered to. In addition, economists define costs as the forgone 
value of alternative uses of resources; consequently, exclusion of costs from CER 
leads to underestimation of the NET value of effective interventions. CER  
will then fail to identify the intervention with the highest net value among 
alternatives with similar effectiveness and harms but different costs. Clinically 
superior interventions can also have lower net value than inexpensive (effective) 
alternatives. CONCLUSIONS: CER without account for patient preferences and 
economic costs can in some cases lead to rejecting interventions which although 
less effective than alternatives, may still have greater net societal value.  
The latter would reduce economic efficiency and lower societal welfare. Findings 
raise questions about the validity of two prevailing evaluation strategies:  
to conduct economic evaluations only if clinical superiority is first established 
and to use CER with priority for the evaluation of the most expensive 
interventions.  
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OBJECTIVES: The OCER literature that evaluates comparative effectiveness of 
alternative medical intervention using existing databases has seen explosive 
growth in the use of PSM in recent years. However, different PSM algorithms 
(e.g., one-to-one, one-to-many, radius matching etc.) yield different estimates of 
the treatment effect. Moreover, matching-induced attrition in the original 
sample may change the target population for which the average treatment effect 
(ATE) was intended. This paper, using a real-world example, proposes a range of 
ATEs that results from different PSM algorithm instead of a single ATE that is 
typically reported in the literature. METHODS: Data for the empirical example 
come from health care claims and clinical information from electronic health 
records in a large U.S. hospital on patients that underwent hysterectomy with 
robotic (N=315) and abdominal (N=265) approaches. The ATE of interest is the 
predicted difference in 6-week all-cause costs starting from index surgery date. 
Baseline characteristics including age, race, insurance type, BMI, comorbidities 
and other clinical characteristics adjusted in each of the 8 PSM models. 95% 
confidence interval (CI) for the range of ATE is obtained through 500 bootstrap 
repetitions. Generalized linear modeling approach was used to model skewed 
costs. RESULTS: Following eight PSM algorithms were implemented: one-to-one, 
one-to-many (with replacement), 3 radius matching with caliper=0.01, 0.001 and 
0.0001, kernel matching, and local linear regression matching. Robotic approach 
was found costlier with its costs varying between $16,713 and $17,522, while 
abdominal costs varied between $13,326 and $14,615. The minimum predicted 
cost difference was $2,812 (95%CI: $1,186; $4,437) while the maximum difference 
was $3,892 (95% CI: -$13, $7,796). As expected, the attrition in the matched 
sample size was highest in radius matching with caliper=0.0001. CONCLUSIONS: 
The range for ATEs instead of a single ATE from a specific PSM algorithm 
provides a better understanding of minimum and maximum possible benefit of a 
medical intervention.  
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OBJECTIVES: Traditional randomized trials are the gold-standard for clinical 
research but may be long, expensive and, especially for CER, inefficient  
in providing evidence to practicing clinicians. We, the REsearch in ADAptive 
methods for Pragmatic Trials (RE-ADAPT) investigators sought to test efficiency 
gains in CER trials by redesigning, then re-executing ALLHAT using adaptive trial 
methodologies. METHODS: ALLHAT was a traditionally designed, large 
comparative trial looking at long-term cardiovascular outcomes with different 
classes of anti-hypertensive drugs compared with diuretics. We prospectively 
developed seven Bayesian adaptive designs incorporating combinations of early 
success/futility stopping, adaptive randomization, and arm dropping. Using  
only information available when ALLHAT was designed, we examined operating 
characteristics of the designs to evaluate clinical and economic efficiencies (e.g. 
shorter trials, greater allocation to superior treatments). One design was chosen 
a priorias the one we would have adopted for ALLHAT, including adaptive 
randomization with the potential for early stopping. The design was executed 
using the ALLHAT data, preserving accrual order and re-sampling patients  
when adaptive randomization called for additional patients in a given  
arm. RESULTS: ALLHAT enrolled 42,418 patients in four years, following patients 
for an additional four years and showed that none of the comparator treatments 
were superior to diuretics. The recommended adaptive design reached the  
same conclusion as the original ALLHAT trial but would have stopped nearly  
one year earlier. Also, the simulated trial randomized 28% more patients to 
calcium channel blockers, because it initially outperformed other arms  
during the accrual stage of the trial. CONCLUSIONS: CER trials are important  
to clinical research. However, conventional methods – even with early  
stopping rules as in ALLHAT – can be so time-consuming, that the clinical 
relevance of the study may be diminished before the results are published. 
Adaptive methods, tailored to CER, can be more efficient, and produce more 
timely evidence.  
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OBJECTIVES: In recent years, biologics, such as tumor necrosis factor inhibitors 
and integrin receptor antagonists have been shown to be effective in the 
treatment of moderate to severe Crohn’s disease, and have changed the 
treatment paradigm. However, there are no direct or indirect comparisons 
establishing the relative efficacy of these treatments.The aim is to compare the 
effectiveness of approved biologics for the induction of clinical response and 
remission in moderate to severe Crohn’s disease. METHODS: A systematic 
literature review searching EMBASE, MEDLINE, and the Cochrane Central 
Register of Controlled Trials was conducted to identify all randomized placebo 
controlled trials (RCT) of biologics in the treatment of moderate to severe Crohn’s 
disease. Bayesian NMA models were developed to analyze clinical response 
(decrease in CDAI score >70 or 100) and remission (CDAI score <150) at the 
longest follow up. RESULTS: Eleven RCTs (3 natalizumab, 3 adalimumab, 4 
certolizumab and 1 infliximab) were included. All biologics performed 
significantly better than placebo in inducing response and remission. In 
comparison to each other, we found that adalimumab and infliximab had higher 
odds-ratio (OR) for inducing clinical response as compared to certolizumab (OR 
1.56, 95% CI 1.06-2.32 and OR 3.80, 95% CI 1.12-18.88 respectively). However, 
sensitivity analysis using response defined as decrease in CDAI >70 only, showed 
there was no significant difference between the biologics. Additionally, 
adalimumab had higher odds of inducing remission compared to natalizumab 
(OR 1.89, 95% CI 1.12-3.26) and certolizumab (OR 2.06, 95% CI 1.20-3.59). 
CONCLUSIONS: Our indirect treatment comparison confirms the findings of 
direct evidence that biologics are effective in the treatment of moderate to 
severe Crohn’s disease. Our results on clinical response were found to be 
sensitive to the definition of clinical response used in the trials. We found that 
adalimumab performed better than natalizumab and certolizumab in inducing 
clinical remission.  
